Drug Pricing Insights
A new GLP-1 drug is making waves with its remarkably low price point, significantly undercutting competitors like Ozempic and Wigovi. The absence of FDA approval allows the company to sidestep costly regulatory hurdles while tapping into a booming market. However, concerns loom over the sustainability of this strategy once existing drug shortages are resolved. Investors should keep a close eye on future developments in this rapidly changing landscape.In this clip
From this podcast
The Prof G Pod with Scott Galloway
Prof G Markets: Nvidia’s Blowout Earnings & Stock Split + Britain’s Damaged Economy
Related Questions